Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.
Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.
The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.
In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.
Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.
Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.
Viridian Therapeutics (Nasdaq: VRDN) announced the grant of non-qualified stock options to an employee for 215,000 shares of common stock, approved by its Compensation Committee. This Inducement Grant, dated December 1, 2022, is outside the 2016 Equity Incentive Plan but adheres to its terms. The exercise price aligns with the stock's closing price on the grant date, and shares will vest over four years. Viridian focuses on treatments for serious diseases, with its lead program targeting thyroid eye disease (TED) through differentiated monoclonal antibodies.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The conference will feature a fireside chat at 10:30 a.m. ET, available via a live webcast on the company's website. Viridian is focused on developing innovative treatments for serious diseases, notably through its monoclonal antibody programs targeting thyroid eye disease (TED). Key products include VRDN-001, VRDN-002, and VRDN-003, which offer convenient dosing options for patients suffering from TED.
Viridian Therapeutics (NASDAQ: VRDN) reported significant progress in its Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), showing rapid clinical improvement after two infusions. The company has initiated the global Phase 3 THRIVE clinical program. As of September 30, 2022, cash and equivalents totaled $431 million, extending its financial runway into the second half of 2025. The third-quarter net loss increased to $28.9 million, up from $14.0 million year-over-year, primarily due to rising R&D and administrative expenses.
Viridian Therapeutics announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for thyroid eye disease (TED). Key findings include:
- 75% proptosis response rate
- 75% overall response rate
- Safety profile remains favorable at 20 mg/kg dose
The study supports the transition to a global Phase 3 THRIVE program, with proof-of-concept data for VRDN-002 expected in 2H23. The company is well-capitalized with $431M, securing operations into 2H25.
Viridian Therapeutics (NASDAQ: VRDN) will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on November 15, 2022. The company will host a fireside chat at 1:35 p.m. ET. Investors can access the live webcast and subsequent replay through the company's Investors section. Viridian is focused on developing treatments for serious diseases, including thyroid eye disease.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will announce its financial results for Q3 2022 on November 14, 2022, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET, accessible via phone or live webcast. The company focuses on developing treatments for serious diseases, with its leading program, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease (TED). VRDN-002 and VRDN-003 are enhanced versions of this therapy, aimed at improving patient convenience.
Viridian Therapeutics presented promising data for VRDN-001, an anti-IGF-1R antibody, during three late-breaking presentations at the American Thyroid Association (ATA) 91st Annual Meeting. The Phase 1/2 trial showed an 83% proptosis response and significant reductions in clinical activity scores among patients with active thyroid eye disease (TED) after receiving two 10 mg/kg infusions. The pivotal program for VRDN-001 is scheduled to start this quarter, with additional data from the 20 mg/kg cohort expected soon.
Viridian Therapeutics (VRDN) announced three key presentations at the upcoming Annual Meeting of the American Thyroid Association (ATA) from October 19-23, 2022, in Montreal. These include late-breaking data for VRDN-001 from its Phase 1/2 trial in Thyroid Eye Disease, highlighting its potential as a best-in-class IGF-1R antagonist. The presentations aim to detail the efficacy and differentiation of VRDN-001 compared to existing therapies. Investors can expect further updates on clinical trial results and pharmacokinetics later this quarter.
Viridian Therapeutics (Nasdaq: VRDN) announced the approval of stock options to purchase 103,000 shares of common stock for three new employees as part of Inducement Grants on September 1, 2022. These grants, made outside the company's Amended and Restated 2016 Equity Incentive Plan, aim to incentivize new hires in line with Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing stock price on the grant date, with a four-year vesting period, beginning with 25% vesting on the first anniversary of employment.
Viridian Therapeutics (NASDAQ: VRDN) announced the issuance of 1,725,000 additional shares at $23.50 each, raising approximately $40.5 million. This follows the previous public offering of 11,352,640 shares, totaling around $311 million in gross proceeds. The funds will support clinical development programs, working capital, and general purposes. The offering was facilitated by Jefferies, SVB Securities, and Evercore ISI. Viridian is focused on developing treatments for underserved diseases, with key programs aimed at thyroid eye disease.
FAQ
What is the current stock price of Viridian Therapeutics (VRDN)?
What is the market cap of Viridian Therapeutics (VRDN)?
What does Viridian Therapeutics, Inc. do?
What is VRDN-001?
What condition does Viridian Therapeutics aim to treat?
How does VRDN-001 work?
Who are Viridian Therapeutics' partners?
What is the financial condition of Viridian Therapeutics?
Why is thyroid eye disease a focus for Viridian Therapeutics?
How can I stay updated on Viridian Therapeutics' progress?
Where is Viridian Therapeutics listed?
What makes Viridian Therapeutics' approach unique?
